Oculis Holding AG (OISE:OCS) Tariff Resilience Score: 6/10 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:OCS Oculis Holding AG OISE:OCS
26 GF Score
Price kr1,350.00
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Tariff Resilience Score?

Oculis Holding AG OISE:OCS -1.10% 26 Tariff Resilience Score is 6 as of Jul. 31, 2026. GuruFocus rates OISE:OCS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,368 Biotechnology companies, Oculis Holding AG ranks better than 76.02% on this metric.

Oculis Holding AG has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Oculis Holding AG has Oculis Holding AG's pharmaceutical focus limits its exposure to tariffs. However, its global supply chain for raw materials and sales markets introduces some vulnerability. The company has moderate mitigation strategies in place.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Oculis Holding AG might have Average Resilient.

Oculis Holding AG  (OISE:OCS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Oculis Holding AG Tariff Resilience Score Related Terms

OISE:OCS vs RIGL, GYRE, SGP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Oculis Holding AG's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Tariff Resilience Score falls into.


OISE:OCS
26GF Score
Oculis Holding AG OISE:OCS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Oculis Holding AG (OISE:OCS) has a Tariff Resilience Score of 6 as of Jul. 31, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Oculis Holding AG ranks #328 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is Oculis Holding AG's Tariff Resilience Score too high?
Oculis Holding AG's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Oculis Holding AG's value of 6 is 50% above this industry median. Based on the distribution chart, Oculis Holding AG ranks #328 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Tariff Resilience Score compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #328 out of 1368 companies for Tariff Resilience Score. This places Oculis Holding AG in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Oculis Holding AG's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oculis Holding AG's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oculis Holding AG's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OISE:OCS) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Oculis Holding AG (OISE:OCS), the current Tariff Resilience Score is 6 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Other Exchanges OCS:USACR5:Germany
Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score

Get the complete analysis for OISE:OCS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,350.00
Price